Voyager Therapeutics, Inc. (VYGR) has a negative trailing P/E of -1.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -52.10%.
Criteria proven by this page:
Overall SharesGrow Score: 68/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -8.0 | 0.10 | 2.37 | 22.67 | - |
| 2017 | -6.3 | -0.10 | 3.32 | 43.90 | - |
| 2018 | -3.4 | -0.82 | 6.49 | 39.56 | - |
| 2019 | -11.5 | 0.20 | 5.03 | 4.80 | - |
| 2020 | 7.2 | -0.04 | 1.72 | 1.55 | - |
| 2021 | -1.4 | 0.01 | 1.07 | 2.73 | - |
| 2022 | -5.0 | 0.16 | 3.96 | 5.72 | - |
| 2023 | 2.7 | -0.01 | 1.54 | 1.45 | - |
| 2024 | -5.0 | 0.04 | 1.09 | 4.09 | - |
| 2025 | -1.9 | -0.02 | 1.18 | 5.71 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.59 | $14.22M | $-40.19M | -282.7% |
| 2017 | $-2.64 | $10.14M | $-70.7M | -697.6% |
| 2018 | $-2.75 | $7.62M | $-88.29M | -1158.8% |
| 2019 | $-1.14 | $104.39M | $-40.83M | -39.1% |
| 2020 | $0.98 | $171.13M | $36.74M | 21.5% |
| 2021 | $-1.75 | $37.42M | $-66.03M | -176.5% |
| 2022 | $-1.21 | $40.91M | $-46.41M | -113.4% |
| 2023 | $2.97 | $250.01M | $132.33M | 52.9% |
| 2024 | $-1.13 | $80M | $-65M | -81.3% |
| 2025 | $-2.04 | $40.37M | $-119.72M | -296.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.81 | $-2.68 – $-1.03 | $53.06M | $27.04M – $81.5M | 10 |
| 2027 | $-1.72 | $-2.43 – $-1.20 | $57.26M | $48.56M – $80.12M | 9 |
| 2028 | $-1.60 | $-3.05 – $0.06 | $75.42M | $75.42M – $75.42M | 7 |
| 2029 | $-1.40 | $-2.79 – $-0.44 | $96.41M | $45.5M – $170.6M | 2 |
| 2030 | $-1.24 | $-2.48 – $-0.39 | $95.06M | $44.86M – $168.21M | 5 |
